Teleflex Reports Innovative Results from Ringer PBC Study
Exciting Developments from the Ringer™ PBC IDE Study
Teleflex Incorporated, a prominent global provider of medical technologies, recently announced the preliminary insights from its Ringer™ PBC IDE study. These results were unveiled during a significant session at the CTO Plus Conference, where the principal investigator, Dr. David E. Kandzari, shared essential findings with attendees. As the Chief of the Piedmont Heart Institute and a leading figure in interventional cardiology, Dr. Kandzari's expertise brings considerable weight to the research.
Understanding Ringer™ PBC and Its Unique Features
The Ringer™ PBC is an innovative device designed for rapid exchange during percutaneous transluminal coronary angioplasty (PTCA). This catheter features a distinctive helical balloon that, when inflated, resembles a hollow cylinder with a substantial central perfusion lumen. This design allows continuous coronary blood flow, a critical factor during prolonged inflations to support patient recovery during coronary procedures.
The Study's Purpose and Methodology
This prominent study is a limited, prospective, multi-center, single-arm IDE investigation, which took place across four clinical sites in the United States. Its central goal was to evaluate the safety and effectiveness of the Ringer™ PBC for managing emergent coronary perforations, a serious complication that can arise during percutaneous coronary interventions (PCI). The study successfully enrolled 30 participants, with analyses based on the intention-to-treat principle. Primary efficacy markers included successful delivery and inflation of the Ringer™ PBC at the perforation site, control of extravasation, and ensuring sustained antegrade coronary flow.
Results and Promising Outcomes
From the 30 participants involved, an impressive 22 achieved the primary efficacy endpoint, translating to a 73.3% success rate. Notably, successful delivery of the Ringer™ PBC was accomplished for 26 participants, marking an 86.7% success rate in these critical cases. Among those who experienced successful delivery, 84.6% successfully controlled extravasation with perfusion. The study also identified that twelve participants required a covered stent post-treatment, while a small number faced emergency surgery or unfortunate outcomes despite perfusion control.
Importance of the Study Findings
Dr. Kandzari emphasized the significance of these preliminary findings, stating, "Treatment options for patients with coronary artery perforations during PCI cases have been limited to date, and this trial points the way to developing dedicated devices." The statement reflects a growing need for advancements in treatment solutions, reiterating the necessity for innovative devices like the Ringer™ PBC.
Regulatory Recognition and Future Prospects
In a notable milestone for the Ringer™ PBC, it received the FDA's Breakthrough Device Designation aimed at expediting the development and approval process for medical technologies providing effective treatment for severe conditions. This designation underscores Teleflex's commitment to enhancing therapeutic options for healthcare practitioners and their patients.
About Teleflex Incorporated
Teleflex is at the forefront of medical technology, dedicated to improving healthcare outcomes and enhancing the quality of life for individuals globally. The company’s diverse product portfolio spans various therapeutic fields, including anesthesia, emergency medicine, interventional cardiology, and surgical solutions. Their commitment to innovation empowers healthcare professionals with tools to deliver high-quality care. Teleflex's renowned products include trusted brands like Arrow™, Barrigel™, Deknatel™, and LMA™, each reflecting a commitment to excellence in medical technology.
Frequently Asked Questions
1. What is the Ringer™ PBC?
The Ringer™ PBC is a specialized PTCA catheter designed to manage coronary blood flow during prolonged inflation in PCI procedures.
2. What were the key findings from the study?
The study found a 73.3% primary efficacy endpoint success rate and an 86.7% successful delivery rate among participants.
3. Why is the Breakthrough Device Designation important?
This designation expedites regulatory pathways to provide critical medical devices faster to patients and healthcare providers.
4. Who is leading the Ringer PBC study?
The study is led by Dr. David E. Kandzari, a respected expert in interventional cardiology and Chief at the Piedmont Heart Institute.
5. What does Teleflex aim to achieve with its products?
Teleflex aims to deliver innovative medical technologies that improve healthcare quality, ensuring optimal patient outcomes.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
